Report on Psychedelics

In The Briefing for June 8th:

Non-profit pushes for psychedelic exemptions.

A new study demonstrates psilocybin’s impact on ego-loss.

Wave of cannabis companies pivot to psychedelics.

Tabula Rasa launches psychedelic incubator.

Mindbloom is a mental health and wellbeing company on a mission to help people expand their human potential.

We spoke with Dylan Beynon, founder and CEO of Mindbloom about what drove him to found the company, his mission to make mental healthcare more accessible and his views on the future of psychedelics and much more.

In the RoP Briefing for the week of June 1st:

Oregon activists submit signatures

MindMed adds MDMA to pipeline

Numinus adds key advisor, announces scale-up plans

Red Light Holland makes CSE debut

Mindmed is a neuro-pharmaceutical company that discovers, develops and deploys psychedelic inspired medicines to improve health, promote wellness and alleviate suffering.

We spoke with co-CEO JR Rahn about his path as an entrepreneur, the company’s approach to tackling the opioid crisis and their intellectual property strategy.

In The RoP Briefing for the Week of May 25th:

Orthogonal Thinker Creates a New Charitable Foundation

Largest Ever DMT Survey Demonstrates Consistent Experience

New Wave to Launch Functional Mushroom Products

Empower to Acquire Certain Rights to the Documentary Dosed

Bright Minds Biosciences is a biotech company with a team of veteran drug hunters, creating the next generation of psychedelics to treat mental health disorders.

RoP spoke with CEO Ian McDonald and in-house Scientist Dr. Gideon Shapiro about their unique approach to drug discovery and what they think is wrong with the current approach to psychedelics.

In the RoP Briefing for the week of May 19th:

MAPS Release Positive Results from Phase 3 Trials

Numinus Wellness Inc to Begin Public Trading

Champignon Brands Launches US Expansion

Portland Activists Shift Decriminalization Strategy

Brightminds Bio is a biotech company with a team of veteran drug hunters, creating the next generation of psychedelics to treat mental health disorders.

RoP spoke with CEO Ian McDonald and in-house Scientist Dr. Gideon Resnick about their unique approach to drug discovery and what they think is wrong with the current approach to psychedelics.

In the RoP Briefing for the Week of May 11th:

DC Decriminalization Effort Finally Catches A Break

New York Lawmakers Contemplate Decriminalization

Entheon Biomedical Opens Financing to Kickstart Trials

New Netflix Show Shares Celebrity Trips

Experts Are Saying Not So Fast To Self-Medicating

The Worst Press Release Gets Worse

Numinus is creating a network of transformative healing centres across North America. Their first location, in Vancouver, offers a range of integrative treatments, with plans to offer psychedelic based therapies in short order. Numinus recently merged with Salvation Botanicals, a BC based licensed narcotics dealer, allowing them to test, produce and sell certain psychedelic substances.

RoP spoke with Numinus’ co-founder and CEO Payton Nyquvest about his personal experience managing health issues with psychedelics, Numinus’s expansion plans, financing and their soon to be public offering.